Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile
Authors:
- 1 September 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (9) , 4427-4429
Abstract
Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).Keywords
This publication has 14 references indexed in Scilit:
- Clostridium difficile infection: new developments in epidemiology and pathogenesisNature Reviews Microbiology, 2009
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile InfectionAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficileAntimicrobial Agents and Chemotherapy, 2008
- Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral DosesAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004Antimicrobial Agents and Chemotherapy, 2007
- Pharmacodynamic Studies of Vancomycin, Metronidazole and Fusidic Acid against Clostridium difficileChemotherapy, 2007
- Alternative treatments for Clostridium difficile disease: what really works?Journal of Medical Microbiology, 2005
- Activity of OPT-80, a Novel Macrocycle, Compared with Those of Eight Other Agents against Selected Anaerobic SpeciesAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activity of OPT-80 against Clostridium difficileAntimicrobial Agents and Chemotherapy, 2004
- Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacinAntimicrobial Agents and Chemotherapy, 1992